Matribhumi Samachar English
Montreal, Quebec–(Newsfile Corp. – April 24, 2026) – Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), (“Defence” or the “Company“), a publicly traded biotechnology and precision intracellular drug-delivery company, wishes to announce that the board of directors of the Company approved the grant of 200,000 incentive restricted stock units (“RSUs“) to …
Read More »Defence Therapeutics Announces Warrant Terms Amendment
Montreal, Quebec–(Newsfile Corp. – March 20, 2026) – Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company“), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce an amendment to the terms of a total of 800,000 Common Share purchase warrants (the “Warrants“) originally issued …
Read More »Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000
Montreal, Quebec–(Newsfile Corp. – March 9, 2026) – Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), (“Defence” or the “Company“), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the closing of a private placement (the “Private Placement“) of 17,445,455 units (the “Units“) at a price of …
Read More »Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March
Montreal, Quebec–(Newsfile Corp. – March 2, 2026) – Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (“Defence” or the “Company”), a publicly traded biotechnology company advancing next-generation therapeutics using its proprietary Accum® platform, today outlined its participation in a series of major international industry events taking place in March …
Read More »Defence Therapeutics Announces Private Placement of Units for Proceeds of up to $11 Million
Montreal, Quebec–(Newsfile Corp. – February 27, 2026) – Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the launch of a private placement (the “Private Placement“) of up to 20,000,000 units (the “Units“) at a …
Read More »Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board
Montreal, Quebec–(Newsfile Corp. – February 10, 2026) – Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (“Defence” or the “Company”), a publicly traded biotechnology and precision intracellular drug-delivery company, reported on its Scientific Advisory Board (“SAB”) meeting held on January 30, 2026, focused on advancing the strategic positioning of Accum® …
Read More »Defence Therapeutics Announces AGM Results and Provides Corporate Updates
Montreal, Quebec–(Newsfile Corp. – December 10, 2025) – Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (“Defence” or the “Company”), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announce that the Shareholders approved …
Read More »Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs
Montreal, Quebec–(Newsfile Corp. – December 4, 2025) – Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (“Defence” or the “Company”), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announce the formation of its …
Read More »Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology
Montreal, Quebec–(Newsfile Corp. – June 9, 2025) – Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company“), a leading biotechnology company specializing in drug delivery technologies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its U.S. …
Read More »Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub
Montreal, Quebec–(Newsfile Corp. – June 2, 2025) – Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a leading biotechnology company specializing in advanced endosomal escape technologies, is pleased to announce the opening of its first U.S. laboratory in the Boston-Cambridge area. This strategic expansion marks Defence …
Read More »